Related Experiment Video
Updated: Aug 13, 2026
08:15
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Attention network dysfunction and treatment response of geriatric depression
Christopher F Murphy1, George S Alexopoulos
1Department of Psychology, Weill Medical College of Cornell University, White Plains, NY 10605, USA. cfm2001@med.cornell.edu
Journal of Clinical and Experimental Neuropsychology
|February 2, 2006
Summary
Executive attention network efficiency predicts antidepressant treatment response in older adults with major depression. This finding may guide future neuroimaging research into depression treatment mechanisms.
Area of Science:
- Neuroscience
- Psychiatry
- Gerontology
Background:
- Major depression is a prevalent condition in older adults, often associated with cognitive impairments.
- Attention networks, including executive, orienting, and vigilance, play crucial roles in cognitive function.
- Understanding factors influencing treatment response is vital for improving geriatric mental healthcare.
Purpose of the Study:
- To investigate the efficiency of attention networks in older patients with major depression.
- To examine the association between attention network efficiency and response to antidepressant treatment.
Main Methods:
- Utilized the Attention Network Test (ANT) to measure executive, orienting, and vigilance attention networks.
- Compared performance between older adults with major depression and healthy controls.
- Analyzed the correlation between attention network performance and time to remission in the depressed group.
Main Results:
- No significant differences in overall attention network performance were found between depressed patients and controls.
- Within the depressed group, executive-related attention performance significantly correlated with time to remission.
- Orienting and vigilance attention network performance did not correlate with treatment response.
Conclusions:
- Executive attention network efficiency is a potential predictor of antidepressant treatment response in older adults with major depression.
- These findings support further investigation into the functional neuroanatomy underlying antidepressant response.
- Targeted neuroimaging studies can elucidate the neural mechanisms linking executive attention and treatment outcomes.
Related Concept Videos
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:18Depression: Overview
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...